Microparticles and Kawasaki disease: a marker of vascular damage?

被引:0
|
作者
Guiducci, S. [1 ]
Ricci, L. [2 ]
Romano, E. [1 ]
Ceccarelli, C. [1 ]
Distler, J. H. W. [3 ,4 ,6 ]
Miniati, I. [1 ]
Calabri, G. B. [5 ]
Distler, O. [3 ,4 ]
Matucci-Cerinic, M. [1 ]
Falcini, F. [1 ]
机构
[1] Univ Florence, Div Rheumatol, Dept BioMed, DENOThe Ctr, I-50139 Florence, Italy
[2] Univ Florence, Dept Paediat, I-50139 Florence, Italy
[3] Univ Zurich Hosp, Zurich Ctr Integrat Human Physiol, CH-8091 Zurich, Switzerland
[4] Univ Zurich Hosp, Ctr Expt Rheumatol, CH-8091 Zurich, Switzerland
[5] Anna Meyer Hosp, Cardiol Unit, Florence, Italy
[6] Univ Erlangen Nurnberg, Erlangen, Germany
关键词
microparticles; Kawasaki disease; ENDOTHELIAL MICROPARTICLES; PLATELET MICROPARTICLES; SYSTEMIC VASCULITIS; CELLS; INFLAMMATION; ACTIVATION; EXPRESSION; APOPTOSIS; DIAGNOSIS; CHILDREN;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Microparticles (MPs) are increased in diseases characterised by endothelial injury. Kawasaki disease (KD) damages the endothelium provoking life-threatening involvement of coronary arteries. Objective. To compare KD MPs vs. controls. Methods. Thirty KD and 20 controls were enrolled. MPs were stained with monoclonal antibodies against platelets, endothelial cells (EC), monocytes, T and B cells, neutrophils, and quantified by FACS. Results. The total number of MPs was significantly increased in KD versus controls (193x10(5)+/- 0.6x10(5) vs. 94x10(5)+/- 0.9x10(5) million/ml plasma p=0.01) and vs. KD after IVIG therapy (132x10(5)+/- 0.4x10(5)million/ml plasma p=0.01). EC and T cells were the major source of MPs in KD (72x10(5)+/- 1x10(5)vs.3x10(5)+/- 0.9x10(5) million/ml plasma for T cells p=0.005; 76x10(5)+/- 0.7x10(5) vs. 45x10(5)+/- 0.4x10(5) million/nil plasma for EC p<0.02) followed by MPs derived from platelets (13x10(5)+/- 0.3x10(5) vs. 3x10(5)+/- 0.9x10(5) million/ml plasma p=0.028). Cell-derived MPs B were 17x10(5)+/- 0.4x10(5) vs. 20x10(5)+/- 0.8x10(5)million/ml plasma in controls (p=0.7). No significant differences were observed in KD MPs derived from monocytes and neutrophils. After IVIG administration, a significant decrease of MPs derived from platelets (3x10(5)+/- 0.2x10(5) million/ml plasma p=0.03), EC (9x10(5)+/- 0.4x10(5) million/ml plasma p=0.01), T cells (72x10(5)+/- 1x10(5) million/ml plasma p=0.02) and B cells (7x10(5)+/- 0.3x10(5) million/nil plasma p=0.02) was observed. Conclusion. The number of KD MPs is significantly increased and EC and T cells are the major source. MPs may develop from endothelial damage and cell activation. Their role as markers of disease activity or as contributors to endothelial derangement in KD has to be further investigated.
引用
收藏
页码:S121 / S125
页数:5
相关论文
共 50 条
  • [41] Epigenetic Regulation of Macrophage Marker Expression Profiles in Kawasaki Disease
    Guo, Mindy Ming-Huey
    Chang, Ling-Sai
    Huang, Ying-Hsien
    Wang, Feng-Sheng
    Kuo, Ho-Chang
    FRONTIERS IN PEDIATRICS, 2020, 8
  • [42] Plasma endothelial microparticles, TNF-α and IL-6 in Kawasaki disease
    Tan, Zhen
    Yuan, Yan
    Chen, Sun
    Chen, Yi
    Chen, Tong-Xin
    INDIAN PEDIATRICS, 2013, 50 (05) : 501 - 503
  • [43] Platelet microparticles and the relationship to the severity of atherosclerotic vascular disease
    Tan, KT
    Tayebjee, MH
    Blann, AD
    Lynd, C
    Lip, GYH
    EUROPEAN HEART JOURNAL, 2004, 25 : 348 - 348
  • [44] Circulating endothelial progenitor cells, microparticles and vascular disease
    Mehta, Jawahar L.
    Szwedo, Jacob
    JOURNAL OF HYPERTENSION, 2010, 28 (08) : 1611 - 1613
  • [45] Cellular microparticles: new players in the field of vascular disease?
    Diamant, M
    Tushuizen, ME
    Sturk, A
    Nieuwland, R
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2004, 34 (06) : 392 - 401
  • [46] SERUM ACID SPHINGOMYELINASE AS A MARKER AND MEDIATOR OF VASCULAR DAMAGE
    Kiprianos, Allan P.
    Church, Leigh D.
    Little, Mark
    Savage, Caroline O.
    Bacon, Paul A.
    Young, Stephen P.
    RHEUMATOLOGY, 2010, 49 : I122 - I123
  • [47] Endothelaemia as a marker of vascular damage in patients with cardiovascular risk
    Kristova, V
    Rajec, P.
    Tisonova, J.
    Dukat, A.
    Kriska, M.
    Varga, I
    Kurtansky, A.
    THERAPEUTIC DRUG MONITORING, 2007, 29 (04) : 551 - 551
  • [48] Erectile dysfunction as a marker for vascular disease
    Billups K.L.
    Current Urology Reports, 2005, 6 (6) : 439 - 444
  • [49] Fibrinogen - marker or mediator of vascular disease?
    Reinhart, WH
    VASCULAR MEDICINE, 2003, 8 (03) : 211 - 216
  • [50] Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension
    Tsai, WC
    Li, YH
    Huang, YY
    Lin, CC
    Chao, TH
    Chen, JH
    CLINICAL SCIENCE, 2005, 109 (01) : 39 - 43